Literature DB >> 15007552

[Hematogenous osteomyelitis in adults].

W Strecker1, M Russ, M Schulte.   

Abstract

Hematogenous osteomyelitis (HOM) in adults is a very rare event in industrialised countries. However, in tropical regions the morbidity of HOM is more important, primarily due to the impact of sickle cell disease, thalassemia, HIV-infection and tuberculosis. HOM is most commonly caused by pyogenic bacteria and mycobacteria, but infections by fungi, viruses and parasites must also be considered. In spite of modern diagnostic procedures such as nuclear and magnetic resonance imaging, the histopathologic and microbiologic examination of bone remains the gold standard for diagnosing OM. Other diagnoses should also be considered. Nonbacterial osteomyelitic lesions (plasmacellular OM, sclerosing OM, SAPHO syndrome) as well as acute leukemia, malignant bone tumors (i.e., Ewing's sarcoma, osteosarcoma) are conditions with similar presentations. Acute HOM is best managed by appropriate antibiotic therapy. In case of failure and in chronic HOM, surgical debridement is mandatory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007552     DOI: 10.1007/s00132-003-0601-4

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  28 in total

1.  Tuberculous osteomyelitis.

Authors:  R Vohra; H S Kang; S Dogra; R R Saggar; R Sharma
Journal:  J Bone Joint Surg Br       Date:  1997-07

2.  Femur osteomyelitis due to a mixed fungal infection in a previously healthy man.

Authors:  M Cimerman; N Gunde-Cimerman; P Zalar; T Perkovic
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 3.  Disseminated infection due to Actinomyces meyeri: case report and review.

Authors:  C Apothéloz; C Regamey
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

4.  Bone and soft tissue manifestations of alveolar echinococcosis.

Authors:  E M Merkle; E Kramme; J Vogel; S Krämer; M Schulte; S Usadel; P Kern; H J Brambs
Journal:  Skeletal Radiol       Date:  1997-05       Impact factor: 2.199

Review 5.  Update on imaging of orthopedic infections.

Authors:  R D Boutin; J Brossmann; D J Sartoris; D Reilly; D Resnick
Journal:  Orthop Clin North Am       Date:  1998-01       Impact factor: 2.472

6.  Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.

Authors:  M Schulte; D Brecht-Krauss; B Heymer; A Guhlmann; E Hartwig; M R Sarkar; C G Diederichs; A Von Baer; J Kotzerke; S N Reske
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

Review 7.  Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment.

Authors:  D W Haas; M P McAndrew
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

8.  Hematogenous osteomyelitis of the hand skeleton in adults after dental maxillary infections.

Authors:  G Germann; A Petracic; M Wittemann; T Raff
Journal:  Ann Plast Surg       Date:  1996-07       Impact factor: 1.539

9.  [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases].

Authors:  A M Chamot; C L Benhamou; M F Kahn; L Beraneck; G Kaplan; A Prost
Journal:  Rev Rhum Mal Osteoartic       Date:  1987-03

10.  Tibial osteomyelitis due to Aspergillus flavus in a heart transplant patient.

Authors:  D De Vuyst; I Surmont; J Verhaegen; J Vanhaecke
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

View more
  2 in total

Review 1.  Invasive aspergillosis osteomyelitis in children--a case report and review of the literature.

Authors:  Anton R Winterstein; Klaus Bohndorf; Kurt Vollert; Theodor Wagner; Astrid Gnekow; Frank W Roemer
Journal:  Skeletal Radiol       Date:  2010-05-30       Impact factor: 2.199

2.  Reciprocal hematogenous osteomyelitis of the femurs caused by Anaerococcus prevotii: A case report.

Authors:  Karolina Daunaraite; Valentinas Uvarovas; Donatas Ulevicius; Tomas Sveikata; Giedrius Petryla; Jaunius Kurtinaitis; Igoris Satkauskas
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.